PROGNOSTIC IMPACT OF MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS WITH NORMAL KARYOTYPE

被引：0

作者：

Montalban-Bravo, G. ^{[1
]}

Pierola, A. Alfonso ^{[1
]}

Takahashi, K. ^{[1
]}

Konopleva, M. ^{[1
]}

Jabbour, E. ^{[1
]}

Brothakur, G. ^{[1
]}

Daver, N. ^{[1
]}

DiNardo, C. ^{[1
]}

Estrov, Z. ^{[1
]}

Kadia, T. ^{[1
]}

Pemmaraju, N. ^{[1
]}

Ravandi, F. ^{[1
]}

Bueso-Ramos, C. ^{[1
]}

Kantarjian, H. ^{[1
]}

Patel, K. ^{[1
]}

Garcia-Manero, G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2017年 / 55卷

关键词：

D O I：

10.1016/S0145-2126(17)30172-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S40 / S40

页数：1

共 50 条

[41] Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future
Arber, Daniel A.
Orazi, Attilio
AMERICAN JOURNAL OF HEMATOLOGY, 2025,
[42] Results of Phase I/ II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations
Montalban-Bravo, Guillermo
Jabbour, Elias
Chien, Kelly S.
Hammond, Danielle E.
Short, Nicholas J.
Ravandi, Farhad
Konopleva, Marina Y.
Borthakur, Gautam
Daver, Naval
Kanagal-Shamanna, Rashmi
Qiao, Wei
Huang, Xuelin
Schneider, Heather
Meyer, Meghan Anne
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[43] NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype
Zhang, Yue
Zhang, Meirong
Yang, Lin
Xiao, Zhijian
LEUKEMIA RESEARCH, 2007, 31 (01) : 109 - 111
[44] Advances in myelodysplastic/myeloproliferative neoplasms
Prakash, Sonam
Arber, Daniel A.
Bueso-Ramos, Carlos
Hasserjian, Robert P.
Orazi, Attilio
VIRCHOWS ARCHIV, 2023, 482 (01) : 69 - 83
[45] Advances in myelodysplastic/myeloproliferative neoplasms
Sonam Prakash
Daniel A. Arber
Carlos Bueso-Ramos
Robert P. Hasserjian
Attilio Orazi
Virchows Archiv, 2023, 482 : 69 - 83
[46] Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Bejar, Rafael
Stevenson, Kristen E.
Caughey, Bennett A.
Abdel-Wahab, Omar
Steensma, David P.
Galili, Naomi
Raza, Azra
Kantarjian, Hagop
Levine, Ross L.
Neuberg, Donna
Garcia-Manero, Guillermo
Ebert, Benjamin L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3376 - 3382
[47] Bone marrow hypocellularity and normal karyotype are the best prognostic factors in myelodysplastic syndromes (MDS)
Pecorari, P
Orlandini, D
Sceusa, R
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 872 - 872
[48] Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
Hebeda K.M.
Fend F.
Journal of Hematopathology, 2009, 2 (4) : 205 - 210
[49] Mixed myelodysplastic and myeloproliferative syndromes
Neuwirtova, R
Mocikova, K
Musilova, J
Jelinek, J
Havlicek, F
Michalova, K
Adamkov, M
LEUKEMIA RESEARCH, 1996, 20 (09) : 717 - 726
[50] CYTOGENETICS OF THE MYELOPROLIFERATIVE AND MYELODYSPLASTIC SYNDROMES
WEGNER, RD
ARZTLICHE LABORATORIUM, 1988, 34 (06): : 193 - 196

← 1 2 3 4 5 →